Patient Leaflet Updated 26-Oct-2022 | MSN Laboratories Europe Ltd
Thiotepa 100 mg powder for concentrate for solution for infusion
Thiotepa 100 mg powder for concentrate for solution for infusion
thiotepa
1. What Thiotepa is and what it is used for
2. What you need to know before you use Thiotepa
3. How to use Thiotepa
4. Possible side effects
5. How to store Thiotepa
6. Contents of the pack and other information
This medicine contains the active substance thiotepa, which belongs to a group of medicines called alkylating agents.
Thiotepa is used to prepare patients for bone marrow transplantation. It works by destroying bone marrow cells. This enables the transplantation of new bone marrow cells (haematopoietic progenitor cells), which in turn enable the body to produce healthy blood cells.
Thiotepa can be used in adults and children and adolescents.
Talk to your doctor before using Thiotepa and if you have:
Because Thiotepa destroys bone marrow cells responsible for producing blood cells, regular blood tests will be taken during treatment to check your blood cell counts.
In order to prevent and manage infections, you will be given anti-infectives.
Thiotepa may cause another type of cancer in the future. Your doctor will discuss this risk with you.
Tell your doctor if you are taking, have recently taken or might take any other medicines.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, you must tell your doctor before you receive Thiotepa.
Both women and men using Thiotepa must use effective contraceptive methods during treatment.
It is not known whether this medicinal product is excreted in breast milk. As a precautionary measure, women must not breast-feed during treatment with Thiotepa.
Thiotepa can impair male and female fertility. Male patients should seek for sperm preservation before therapy is started and should not father a child while treated and during the year after cessation of treatment.
It is likely that certain adverse reactions of thiotepa like dizziness, headache and blurred vision could affect your ability to drive and use machines.
Your doctor will calculate the dose according to your body surface or weight and your disease.
Thiotepa is administered by a qualified healthcare professional as an intravenous infusion (drip in a vein) after dilution of the individual vial. Each infusion will last 2-4 hours.
You will receive your infusions every 12 or 24 hours. The duration of treatment can last up to 5 days. Frequency of administration and duration of treatment depend on your disease.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The most serious side effects of Thiotepa therapy or the transplant procedure may include:
Your doctor will monitor your blood counts and liver enzymes regularly to detect and manage these events.
Side effects of Thiotepa may occur with certain frequencies, which are defined as follows:
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Not known: frequency cannot be estimated from the available data
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP.
The expiry date refers to the last day of that month.
Store and transport refrigerated (2°C-8°C).
Do not freeze.
After reconstitution the product is stable for 8 hours when stored at 2°C -8°C.
After dilution the product is stable for 24 hours when stored at 2°C -8°C and for 4 hours when stored at 25°C. From a microbiological point of view, the product should be used immediately.
Any unused product or waste material should be disposed of in accordance with local requirements.
Thiotepa is a white lyophilized powder supplied in a glass vial containing 100 mg thiotepa.
Each carton contains 1 vial.
This leaflet was last revised in April 2022
Devonshire, Business Centre, Works road, Letchworth Garden City, Herts, SG6 1GJ, UK
020 3371 7158
07789 669 333
www.msnlabs.com
020 3371 7158
07831 268 255